ATH
$120M—
Alterity Therapeutics
Biotechnology · Neurology
Clinical-stage biopharma developing ATH434, an oral iron chaperone targeting pathological iron accumulation in neurodegenerative diseases including multiple system atrophy.
No cash data on fileFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
—
Runway
—Market Cap
$120M
Burn Rate
—
Shares Outstanding
10.9B
Pipeline Assets
3
Latest Insight(1)
29 Mar 2026RegulatoryAlterity Receives Positive FDA Feedback From Type C Meeting
Alterity Therapeutics received positive written feedback from the FDA following a Type C Meeting regarding its planned Phase 3 development program for ATH434 in Multiple System Atrophy, with alignment reached on clinical pharmacology and non-clinical development elements. The company plans further discussions on CMC and Phase 3 trial design, with an End-of-Phase 2 meeting targeted for mid-2026.
FDA·Multiple System Atrophy (MSA)·positive
3M Price
ATH.ASX$0.011+37.5% 3M
Low $0.007High $0.011
Pipeline Assets (3)
ATH434friedreich ataxia
PreclinicalATH434multiple system atrophy
Phase 2ATH434multiple system atrophy
Phase 2Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
Capital Raises & Buybacks
2 raises
Current shares outstanding: 10.9B
Options
Other
2026-03-19options exercise
2026-03-19other
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Short Interest
ASIC ↗as of 2026-03-27 · 4-day lag
Short position
0.04%
arrow_drop_down-0.02% over 2 reports
Shares short
4.7M
Aggregated short position data published by ASIC under the Corporations Act. T+4 reporting lag applies. Short interest ≥5% is noteworthy; ≥10% is elevated. Source: ASIC Short Selling Data
Competitive Landscape
1 approved drug49 competitor trialsPhase 2+ · Non-ASX
Friedreich Ataxia5 active trials
2 Ph31 Ph22 Ph1/PHASE2
Multiple System Atrophy44 active trials
1 Ph45 Ph35 Ph2/316 Ph217 Ph1/PHASE2
Approved
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
expand_moreClinical Publications
Peer-reviewed papers & conference abstracts via PubMed
1 paper
Clinical Publications
Peer-reviewed papers & conference abstracts via PubMed
J Biol Chem2025-09· ATH434
Catalysts (7)· 4 upcoming · 3 past
FDA End-of-Phase 2 meeting
UpcomingExpectedarrow_upwardHigh30 Sept 2026
End-of-Phase 2 meeting with FDA
UpcomingExpectedarrow_upwardHigh30 Sept 2026
ATH434 partnering/licensing deal
UpcomingSpeculativearrow_upwardHigh31 Dec 2026
Phase 3 IND filing / trial initiation
UpcomingSpeculative
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
1/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
–Insufficient data
0/2 data points needed
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Hit 1 of 1 guided dates· rolling 2yr(limited sample)· of 7 tracked
Completed catalysts
✓Alterity Presents New Analysis of ATH434 Phase 2 Data at AAN· readout — subject to clinical uncertainty— ATH434 slowed disease progression on the MuSyCA composite scale with a treatment effect of -1.9 to -4.0 points versus placebo at Week 52 (50 mg dose p=0.034, relative treatment effect 41%), while placebo participants worsened by approximately +9.7 points. Consistent results were also seen on the modified UMSARS Part I, with ATH434 slowing progression by up to -4.7 points at 50 mg (relative treatment effect 53%, p=0.029).
On time
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Clinical Trials(3)
No active trials